Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Moor (Rotterdam, Netherlands). Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis. 4884

Member's Comments

No comment yet.

Related content which might interest you: Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis. Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017 Year: 2017 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005